Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis

Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis

Abstract Background Daratumumab (Dara)-based regimens have been investigated in randomized controlled trials (RCTs) involving patients with newly diagnosed and previously untreated multiple myeloma (NDMM), but the optimal daratumumab-based regimen remains unclear. This study compares the efficacy of...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaohua Huang, Jia Zhou, Yuxiao Qian, Jing He, Lu Yang, Zhigang Wang, Diu Wei, Mengjie Li, Wei Ma, Haiyan Lang
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Systematic Reviews
Subjects:
Daratumumab
Newly diagnosed
Multiple myeloma
Lenalidomide
Component network meta-analysis
Online Access:https://doi.org/10.1186/s13643-025-02804-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13643-025-02804-4

Similar Items